H.C. Wainwright maintains a Buy rating on Lexeo Therapeutics but slashes its price target, citing persistent market doubts over the company's PKP2 cardiomyopathy program despite encouraging early clinical results.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
With gold and silver hitting record highs amid market turbulence, numismatic experts argue that certified rare coins offer a unique blend of tangible value, historical significance, and surprising liquidity for discerning investors.
As XRP hovers around $2, a stark divide emerges between institutional and algorithmic forecasts for its 2026 value. Standard Chartered's bullish $8 target contrasts with more cautious AI projections, with the outcome likely hinging on ETF inflows, regulatory clarity, and real-world adoption.
From delivering pizzas to building a global sportswear empire, Ben Francis's journey to a $1.4 billion net worth is a modern business fable. Yet, in a candid podcast interview, the Gymshark CEO argues that equating self-worth with wealth is a 'wildly unproductive way to live,' offering a rare glimpse into the mindset behind the paper fortune.
A new report highlights how small and medium-sized businesses are leveraging AI, hyper-personalization, and sustainable practices not just to adapt, but to lead in a rapidly evolving marketplace.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
A pivotal week for markets unfolds as Amazon, Alphabet, AMD, and Disney headline a packed earnings calendar. With implied volatility spiking, option traders brace for significant moves across sectors.
Three decades after its birth, New York's Silicon Alley has matured into a distinct tech ecosystem, anchored by profitability, cross-industry ties, and resilience through multiple booms and busts.
Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.
Amphenol Corporation (NYSE: APH), a key player in electronic connectors, received concurrent price target increases from Seaport Research and Citi. While analysts highlight growth potential, the stock's post-earnings dip underscores a cautious market stance toward the company's traditionally conservative guidance.
Investment firm William Blair has initiated coverage on Rambus Inc. with an 'Outperform' rating, highlighting the chip designer's dominant market share in interface circuits and its strategic positioning to capitalize on surging demand from AI data centers and server DRAM upgrades.
A prolonged, nationwide internet blackout in Iran, imposed during recent unrest, has crippled businesses and severed global connections for millions, revealing the deep fragility of an economy already under strain.
Seven Wisconsin employers filed WARN notices in January, yet the state's unemployment rate held steady at a low 3.1%. Economists point to a cooling but stable labor market, with significant workforce changes driven by retirements and sectoral shifts.
As Pzena Investment Management's latest commentary highlights a challenging quarter for value strategies, one of its holdings, freight giant Knight-Swift, comes into focus. We examine the investment case for KNX amidst shifting economic currents and a market dominated by AI hype.
Pzena Investment Management's latest quarterly commentary reveals its Focused Value Strategy lagged behind the broader value index in Q4 2025, with agricultural sciences firm FMC Corporation highlighted as a key underperformer amid a market dominated by AI and mega-cap stocks.
The $12 trillion asset manager founded by Jack Bogle announced another round of expense reductions across 53 funds, saving investors an estimated $600 million over two years and reinforcing its half-century mission of driving down costs for the everyday investor.
A check for $175, signed by Steve Jobs and Steve Wozniak in 1976 to pay an early parts supplier, has sold for a staggering $2.4 million at auction, highlighting the immense value collectors place on artifacts from Apple's humble beginnings.
The automotive tech spinoff from Continental plans significant workforce reductions globally, aiming to lower its R&D expenditure ratio in response to market pressures, with Germany bearing the brunt of the cuts.
Pakistan has announced it will not play its scheduled T20 World Cup match against India, a decision linked by officials to recent deadly attacks in Balochistan and broader geopolitical disputes involving Bangladesh's tournament exclusion.
